9 news items
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
AKRO
12 Jun 24
funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses since its
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
AKRO
5 Jun 24
funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses since its
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
AKRO
29 May 24
funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses since its inception
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
AKRO
22 May 24
funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses since its inception
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Akero Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
AKRO
15 May 24
funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses since its inception
v91162pex91cznkdeh
AKRO
8 May 24
for sale. Because funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses
k1szmafvvaxr41uvo5w8lasu50e bznhk84dbdl3ots9e5aqtblyvkgv
AKRO
8 May 24
funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses since its inception
xobe 2fdu
AKRO
1 May 24
for sale. Because funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses
w0bngyjuo8pf9dxehmy3y8mf306guzlemkt5rt7n8myooa98sg0 8fbaog
AKRO
1 May 24
funding drug development, clinical trials, and commercialization is capital-intensive, Akero has suffered significant recurring losses since its inception
- Prev
- 1
- Next